H.C. Wainwright analyst Ed Arce maintained a Hold rating on Axcella Health (AXLA – Research Report) today. The company’s shares opened today at $0.75.
According to TipRanks, Arce is a 5-star analyst with an average return of 20.9% and a 43.20% success rate. Arce covers the Healthcare sector, focusing on stocks such as Cidara Therapeutics, Enanta Pharmaceuticals, and Albireo Pharma.
Axcella Health has an analyst consensus of Moderate Buy, with a price target consensus of $1.75.
See today’s best-performing stocks on TipRanks >>
AXLA market cap is currently $44.34M and has a P/E ratio of -0.36.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Axcella Health, Inc. is a biotechnology company, which engages in the research and development of novel multifactorial interventions to support health and address dysregulated metabolism across a broad spectrum of consumers and patients who have limited options. Its product pipeline includes AXA1665, AXA1125, AXA1957, AXA2678, and AXA4010. The company was founded by Noubar B. Afeyan, Geoffrey von Maltzahn, and David A. Berry on August 27, 2008 and is headquartered in Cambridge, MA.
Read More on AXLA:
